D-Limonene (R-(+)-limonene)

D-Limonene (R-(+)-limonene) is a cyclic monoterpene found abundantly in citrus peel oil that exerts anticancer and anti-inflammatory effects primarily by modulating Ras protein prenylation, suppressing cyclin D1 expression, and activating apoptotic pathways. It concentrates preferentially in fatty tissues, including breast tissue, making it a candidate adjuvant in oncology research.

Origin & History

D-Limonene is a naturally occurring monoterpene hydrocarbon found primarily in citrus essential oils, with the highest concentrations in orange, lemon, and grapefruit peels. It is extracted through cold pressing or steam distillation of citrus rinds, yielding a cyclic monoterpene with the formula C10H16.

Historical & Cultural Context

No traditional medicine uses were documented in the research provided. Current applications are based entirely on modern preclinical and clinical cancer research rather than historical ethnomedical systems.

Health Benefits

• May support cancer treatment adjuvantly - one breast cancer patient achieved partial response lasting 11 months in phase I trial (preliminary evidence)
• Concentrates in breast tissue (41.3 μg/g) and reduces tumor cyclin D1 expression based on phase II study (n=43)
• Demonstrates anti-inflammatory effects by reducing TNF-α, IL-6, IL-1β and elevating IL-10 in preclinical models
• Induces autophagy and apoptosis in lung cancer cells through autophagic pathway activation (in-vitro evidence)
• Shows antioxidant properties and protection against doxorubicin-induced nephrotoxicity via NF-κB and COX-2 inhibition (animal studies)

How It Works

D-Limonene inhibits the post-translational prenylation of Ras and other small G-proteins by blocking farnesyl pyrophosphate transferase and geranylgeranyl transferase enzymes, disrupting downstream MAPK and PI3K/Akt proliferation signaling. It downregulates cyclin D1, a cell-cycle regulatory protein, thereby arresting tumor cells in G1 phase and reducing uncontrolled mitosis. Additionally, D-Limonene suppresses NF-κB activation and reduces pro-inflammatory cytokine production, including TNF-α and IL-6, contributing to its anti-inflammatory profile.

Scientific Research

Clinical evidence is limited to small phase I/II trials, including a phase I study (n=32, PMID: 9654110) establishing MTD at 8 g/m²/day with one partial response in breast cancer, and a phase II trial (n=43) showing breast tissue accumulation and cyclin D1 reduction. No randomized controlled trials or meta-analyses on D-limonene alone were identified.

Clinical Summary

A phase I dose-escalation trial in breast cancer patients demonstrated that oral D-Limonene produced one confirmed partial response lasting 11 months, establishing preliminary proof-of-concept for anticancer activity at tolerable doses. A subsequent phase II study (n=43) quantified tissue pharmacokinetics, confirming breast tissue concentrations of 41.3 μg/g and a statistically significant reduction in tumor cyclin D1 expression after supplementation. Evidence remains early-stage and limited to small trials without randomized placebo controls, so conclusions about efficacy must be considered preliminary. Anti-inflammatory effects have been documented in preclinical models but have not yet been confirmed in adequately powered human randomized controlled trials.

Nutritional Profile

D-Limonene is a pure monocyclic monoterpene compound (C10H16, molecular weight 136.23 g/mol), not a nutritional food source, so conventional macronutrient/micronutrient framing does not apply. Bioactive compound content: essentially 100% R-(+)-limonene enantiomer when in purified form. Naturally occurs in citrus peel oils at concentrations of 40,000–960,000 mg/kg (40–96% of essential oil composition depending on species); orange peel oil contains approximately 680,000–960,000 mg/kg, lemon peel oil approximately 400,000–700,000 mg/kg. Caloric density as a lipophilic terpene is approximately 8.8 kcal/g (theoretical, as a hydrocarbon), but dietary exposure doses are typically 1–10 g/day in supplemental form, contributing negligible calories in practical use. Contains no protein, carbohydrates, fiber, vitamins, or minerals. Key bioactive properties stem from its monoterpene structure: highly lipophilic (log P ≈ 4.57), enabling strong tissue partitioning — confirmed breast tissue concentration of 41.3 μg/g at supplemental doses of ~2 g/day in human phase II data. Bioavailability: rapidly absorbed orally, undergoes hepatic metabolism to perillic acid, dihydroperillic acid, uroterpenol, and limonene-1,2-diol via CYP450 enzymes (primarily CYP2C19, CYP3A4); urinary metabolite perillic acid reaches plasma concentrations of approximately 30–50 μM at 2 g/day dosing. Half-life approximately 12–24 hours. No dietary fiber, no mineral content, no vitamin content.

Preparation & Dosage

Clinically studied doses range from 0.5-12 g/m²/day in cancer trials, with maximum tolerated dose at 8 g/m²/day (approximately 400-600 mg/kg). Breast tissue studies used 2 g/day for 2-6 weeks. Only pharmaceutical-grade pure D-limonene was studied, not standardized extracts. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Curcumin, Green Tea Extract, Quercetin, Resveratrol

Safety & Interactions

D-Limonene is generally recognized as safe (GRAS) by the FDA at culinary doses and is well tolerated at supplemental doses up to approximately 1–2 g/day in clinical trials, with the most common adverse effects being mild gastrointestinal symptoms such as heartburn, nausea, and belching due to its esophageal sphincter-relaxing properties. Individuals with gastroesophageal reflux disease (GERD) or peptic ulcers should use caution, as it may exacerbate reflux symptoms. D-Limonene is metabolized by CYP1A2, CYP2C9, and CYP3A4 hepatic enzymes, creating a theoretical interaction risk with drugs dependent on these pathways, including warfarin, statins, and certain chemotherapeutics — though clinical interaction data in humans are lacking. Safety in pregnancy and lactation has not been established in controlled human studies, and use should be avoided in these populations without medical supervision.